According to the Center for Cancer Research, National Cancer Institute, in the U.S. around 6 million new cancer are diagnosed in dogs and cots each year. In October 2017, PetCure Oncology and South Carolina Veterinary Specialists & Emergency Care announced a partnership for bringing life-saving cancer care to pet owners in South Carolina and its surrounding areas. PetCure Oncology provides cancer care for cats, dogs and companion animals in the United States and has strategic collaboration with Varian Medical Systems, a company engaged in manufacturing medical devices & software for cancer treatment. The Halcyon treatment system is an equipment installed in South Carolina facility for veterinary application.

Dogs having malignant cancers often cannot be treated by therapies such as radiotherapy, surgeries and chemotherapy. Oral malignant melanoma (OMM) is a highly invasive cancer among dogs. As a result, the Hokkaido University has introduced a chimeric anti-PD-L1 antibody that helps in inducing immune responses and thus, tumor regression in dogs suffering from malignant cancers.

“Advancement in early adoption of diagnosis and treatment of cancer has proven to show success rate in treating and curing cancer in pet population in the recent past. Moreover, pharmaceutical and life science companies in the veterinary industry have also heavily invested their resources to develop robust pipeline of therapies and drugs to provide the best treatment for pets. Emergence of Various Startups and their Work on Biotech Drugs for Pets. A Success Rate or an Indifferent Growth? Company named CanFel Therapeutics is working on veterinary oncology application by developing a new class of cancer-fighting drugs. They are mainly leveraging their biology-driven cCSC development platform by utilizing advanced cell-based discovery technology for the development of feline and canine antibody therapy versions. ”

The detailed research study provides qualitative and quantitative analysis of the global pet cancer therapeutics market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue as well as sales volume across regions and further, across all the major countries. The supply side analysis covers regional production volume and capacity analysis. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Some of the major players operating in the global pet cancer therapeutics market are Advaxis Inc., AdvaVet, Aratana Therapeutics, Inc., ELIAS Animal Health, Boehringer Ingelheim International GmbH, CanFel Therapeutics, Fetch Pharma, Genentech, Karyopharm Therapeutics, Morphogenesis, Inc., Kindred Biosciences, NIPPON ZENYAKU KOGYO CO., LTD., Oasmia Pharmaceutical AB, PetLife Pharmaceuticals, Inc., Pharmaust., Phibro Animal Health Corporation, Regeneus Ltd, Rhizen Pharmaceuticals S.A., Amgen Inc, Torigen Pharmaceutical Inc., Vaccibody, VetDC, Virbac., Innogenics,  Zoetis Services LLC amongst others.

By Animal Type

• Dogs
• Cats
• Horses
• Others

By Cancer Type

• Mast Cell Cancer
• Lymphoma
• Melanoma
• Mammary
• Squamous Cell Cancer
• Others

By Route of Administration

• Oral
• Intravenous
• Others

By Therapy Type

• Chemotherapy
• Targeted Therapy
• Combination Therapy
• Immunotherapy

By Geography

• North America
• U.S.
• Canada
• Mexico
• Rest of North America
• Europe
• France
• The UK
• Spain
• Germany
• Italy
• Nordic Countries
• Benelux Union
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Southeast Asia
• Australia
• New Zealand
• Rest of Asia Pacific
• Middle East and Africa
• GCC Countries
• Southern Africa
• Rest of Middle East and Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America